文献速递泌尿男性生殖肿瘤

晚期肾细胞癌中纳武利尤单抗与伊匹木单抗的优化管理:基于反应的II期研究(OMNIVORE)

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
PubMed 文献 · J Clin Oncol · 2020-10-27

该II期反应适应性试验纳入未接受过检查点抑制剂治疗的转移性肾细胞癌患者,先给予纳武利尤单抗单药,根据反应分配至观察组(A组)或后续伊匹木单抗两剂(B组)。主要终点为A组停药1年后维持PR/CR的比例及B组纳武利尤单抗无反应者经伊匹木单抗转化为PR/CR的比例。结果显示A组42%维持缓解,B组仅4%转化,无CR,不支持反应适应性策略。

要点

  • 纳武利尤单抗诱导后,仅12%患者确认PR,14%进入A组停药观察。
  • A组停药≥1年仍维持缓解者占42%(90% CI 18%–68%)。
  • B组伊匹木单抗转化PR仅4%(90% CI 1%–11%),无CR。

核心结论

  • 纳武利尤单抗后序贯两剂伊匹木单抗无CR且PR/CR转化率低,数据不支持晚期肾细胞癌的反应适应性检查点阻断策略。
  • 评估纳武利尤单抗停药价值的患者数太少,无法判断该方法的益处。

研究设计与样本

  • II期反应适应性试验(NCT03203473),纳入未接受过检查点抑制剂治疗的转移性肾细胞癌患者。
  • 所有患者先接受纳武利尤单抗单药,6个月内确认PR/CR者停药观察(A组),稳定或进展者接受伊匹木单抗两剂(B组)。
  • 共83例患者开始治疗,96%为透明细胞组织学,51%为初治,67%为中/高危。
  • 主要终点为A组停药1年后PR/CR比例及B组纳武利尤单抗无反应者经伊匹木单抗转化为PR/CR的比例。

主要发现

  • 中位随访19.5个月,6个月内纳武利尤单抗诱导确认PR为12%(n=10)。
  • 14例未分配至研究组(7例毒性,7例进展)。
  • 12例(14%)分配至A组并停药,其中5例(42%;90% CI 18%–68%)在≥1年时仍停药。
  • 57例(69%)分配至B组,2例转化为确认PR(4%;90% CI 1%–11%),无CR。

临床怎么用

  • 目前数据不支持在晚期肾细胞癌中根据早期反应决定是否停用纳武利尤单抗或序贯伊匹木单抗的反应适应性策略。
  • 对纳武利尤单抗诱导后停药观察应谨慎,需更多患者数据评估其价值。

局限性

  • 评估纳武利尤单抗停药价值的患者数太少(A组仅12例),无法充分评估该策略。
  • 本研究为单臂II期反应适应性设计,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473). METHODS: We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure. All patients received nivolumab alone with subsequent arm allocation based on response. Patients with a confirmed partial response (PR) or complete response (CR) within 6 months discontinued nivolumab and were observed (arm A). Patients with stable disease or progressive disease (PD) after no more than 6 months of nivolumab received two doses of ipilimumab (arm B). The primary endpoints were the proportion of patients with PR/CR at 1 year after nivolumab discontinuation (arm A) and proportion of nivolumab nonresponders who converted to PR/CR after ipilimumab (arm B). RESULTS: Overall, 83 patients initiated treatment, of whom 96% had clear-cell histology, 51% were treatment naïve, and 67% had intermediate/poor-risk disease. Median follow-up was 19.5 months. Within 6 months, induction nivolumab resulted in a confirmed PR in 12% of patients (n = 10). Fourteen patients were not allocated to a study arm (seven because of toxicity, seven because of PD). Twelve patients (14%) were allocated to arm A and discontinued nivolumab, of whom five (42%; 90% CI, 18% to 68%) remained off nivolumab at ≥ 1 year. Of 57 patients (69%) allocated to arm B, two patients converted to a confirmed PR (4%; 90% CI, 1% to 11%), and no CRs were observed. CONCLUSION: In this study, nivolumab followed by two doses of ipilimumab resulted in no CRs and a low PR/CR conversion. The number of patients evaluated for nivolumab discontinuation was too small to assess the value of this approach. Currently, our data do not support a response-adaptive strategy for checkpoint blockade in advanced RCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McKay RR, McGregor BA, Xie W, et al. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol. 2020. PMID: 33108238. doi:10.1200/JCO.20.02295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。